Monitor for appointment of a permanent CFO and any updates on Vir Bio's pipeline or financial strategy. The interim CFO is an internal appointee with deep accounting experience, so near-term disruption is minimal.
VIR drugs
VIR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 24 $8.69entry
- T+1 · 4mo ago +1.27%α +1.24% · $8.80
- T+5 · 4mo ago +2.42%α +2.04% · $8.90
- T+20 · 3mo ago +12.54%α +8.92% · $9.78
- T+60 · 29d ago +17.49%α +13.76% · $10.21
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vir Biotechnology disclosed that CFO Jason O'Byrne will step down on August 3, 2026 to pursue another opportunity, with no disagreement cited. The company appointed Brent Sabatini, SVP and CAO, as interim principal financial officer effective the same date, and has initiated a search for a permanent successor. This is a routine executive transition with no financial impact disclosed.
Key Facts
- CFO Jason O'Byrne resigning effective August 3, 2026 to pursue another opportunity
- No disagreement with Vir Bio's operations, policies, or practices
- Brent Sabatini appointed interim principal financial officer effective August 3, 2026
- Sabatini will not receive any additional compensation for the interim role
- Company has initiated a search for a permanent CFO
Financial Impact
No financial figures disclosed in the filing
Risk Factors
- Prolonged CFO vacancy could impact investor confidence and financial planning
- Potential for strategic shifts if a new CFO is brought in from outside
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (VIR), Batch item 1 | 0001628280-26-049499 |
| Document: 0001628280-26-049499-index-headers.html | 0001628280-26-049499 |
| Document: 0001628280-26-049499-index.html | 0001628280-26-049499 |
| Document: 0001628280-26-049499.txt | 0001628280-26-049499 |
| 8-K Filing (VIR), Batch item 5 | 0001628280-26-049499 |
| Document: 0001628280-26-049499-index-headers.html | 0001628280-26-049499 |
| Document: 0001628280-26-049499-index.html | 0001628280-26-049499 |
| Document: 0001628280-26-049499.txt | 0001628280-26-049499 |
Track record
36 reports on VIR
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
- Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
- Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
- Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
- Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
- Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers